~latest info at the top~

  • TheBodyPro The next frontiers of U=U science
  • JAMA Association of HIV Preexposure Prophylaxis With Incidence of Sexually Transmitted Infections Among Individuals at High Risk of HIV Infection
  • Dovato, a co-formulation of dolutegravir and lamivudine, approved by FDA 4/8/2019. More info at Medpagetoday.
  • Opioid epidemic is increasing rates of some infectious diseases
  • Raltegravir plus lamivudine is likely to work as PrEP
  • Systematic analysis suggests that circumcision helps protect MSM from infection with HIV
  • Clusters of co-morbidities in people living with HIV show major non-HIV medical needs
  • Viral suppression maintained with alternate-day dosing of efavirenz/tenofovir/emtricitabine
  • Diet and exercise advice lowers diabetes risk in people with HIV
  • Case of On-Demand PrEP Failure Reported in Australia
  • 3-Month Naltrexone Implant Improves HIV, Addiction Treatment Outcomes
  • CROI 2019: Opioid overdose deaths are rising among people with HIV in the United States
  • CROI 2019: Non-adherence to HIV treatment for cost-saving reasons reported by 8% in American study
  • HIV Exposure in Womb Tied to Metabolic Disease in Later Life: Upped risk for immune dysfunction as well, possibly due to inflammation
  • Healthcare providers should discuss U=U with all their HIV-positive patients
  • CROI 2019: High rate of viral suppression among people new to HIV care
  • Many recovering from addiction have chronic health problems, diminished quality of life
  • CROI 2019Video: Paul Volberding on HIV stigma
  • The impact of older antiretrovirals on fat redistribution and cardiovascular risk factors may be irreversible
  • CROI 2019: Trogarzo’s Effects on Hard-to-Treat HIV Are Stable Over Two Years
  • Women, Young People and Medicaid Recipients Are More Likely to Stop PrEP
  • Dolutegravir-based second-line ART achieves excellent virological outcomes even in the presence of resistance to recycled NRTIs
  • Chronic Pain Is a Huge, Underrecognized Problem for People With HIV [POZ]
  • A 3rd Man Received HIV-Resistant Stem Cell Transplant, Is in Viral Remission (it’s too early to say he is “cured”)
  • Latest anti-retroviral drug regimens provide ‘Lazarus Effect’ for HIV patients
  • CROI 2019 How many people who have used PrEP get HIV the same year? New York study finds out
  • CROI 2019 Gay & Bi Men With HIV Cured of Hep C Are Reinfected at High Rate
  • CROI 2019 Early Trial of Gilead’s HIV Capsid Inhibitor Supports 3-Month Dosing
  • CROI 2019 The Viral Reservoir (or cellular clonal expansion) Can Explain Persistent Low Level Viremia With Good Adherence on ART. POZ has another post on this issue.
  • CROI 2019 Neural tube defects and integrase inhibitors: still waiting for stronger evidence
  • CROI 2019 Study Highlights Link Between ART and Weight Gain in Virally Suppressed Participants
  • CROI 2019 Researchers report high rate of viral suppression among people new to HIV care
  • CROI 2019 Individuals With HIV May Be at Higher Risk of Opioid Overdose Death
  • CROI 2019 Depo injection cabotegravir + rilpivirine found to be noninferior at 48 weeks to 3-drug oral ART as well as to dolutegravir/abacavir/lamivudine
  • CROI 2019 TAF/emtricitabine appears to be noninferior to TDF/emtricitabine in MSM, transgender women for PrEP
  • CROI 2019 HIV is a risk for cardiac death if the HIV viral load is not suppressed
  • CROI 2019 A second patient who has received an HIV-resistant bone marrow transplant may be cured of HIV (the famous “Berlin” patient is the first one). More detailed info from theBody.com
  • Ryan White Conference 2018: presentations, handouts, slides, etc.
  • 3/3/2019 Dolutegravir may work as monotherapy in early infection
  • 1/10/2019 Information from the NIH clearly supports U=U which is one of the most destigmatizing concepts for people with HIV.
  • 1/15/2019 PrEP with Truvada may have a negative effect on condom use and STI rates, but if so, PrEP is still worth it in my opinion.
  • 1/21/2019 Even with good treatment, HIV seems to accelerate the aging process.
  • 1/29/2019 Nonalcoholic fatty liver disease may be increasingly common in people with HIV.
  • 2/1/2019  HIV RNA suppression rates are equivalent between Ryan White clinics and the private sector.
  • 2/2/2019 Introducing the single-use genderless internal condom
  • 2/3/2019 STIs drive HIV transmission approximately 10% of the time in gay/bi men.
  • 2/4/2019 The search for the cure is ongoing. Two new types of cell therapy attempt to target the elusive HIV reservoir.
  • 2/5/2019 The intention of the manufacturer to make Oxycontin resistant to abuse by crushing it up, led to an increase in hepatitis C cases
  • 2/8/2019 Researchers identify a new T-cell marker that could help to find better treatment and a cure for HIV
  • 2/9/2019 NIH “U=U” is scientifically valid.
  • 2/10/2019 An immune system receptor may be the key to HIV complications
  • 2/12/2019 Switching from protease inhibitors to integrase inhibitors improved risk factors for diabetes
  • 2/13/2019 Smoking, blood pressure, lipids are important determinants of health in people with HIV
  • 2/15/2019 Smoking pot is linked to higher risk of lung disease in HIV infected men (read the study)
  • 2/23/2019 Only 2 in 5 male PrEP users continue it over 2 years
  • 2/25/2019 Men with hepatitis C may have low testosterone levels

Leave a Reply

%d bloggers like this: